Pharma Pioneer

Preliminary Findings from Phase 1/2 Trial of Gritstone's Universal Neoantigen Vaccine Approach (SLATE) Featured in Nature Medicine

16 May 2024
3 min read

April 15, 2024 —A recent publication in Nature Medicine has highlighted the advancements in vaccine design, specifically focusing on Gritstone bio's neoantigen platform, SLATE. The research, led by Steven A. Rosenberg from the National Cancer Institute, has resulted in a more effective vaccine candidate targeting KRAS, a gene mutation commonly found in various cancers. 

The study, "A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results," reveals a new hierarchy of tumor neoantigens that Gritstone bio discovered during their Phase 1 studies. This discovery was pivotal in the creation of SLATE-KRAS, which has shown stronger immunogenicity compared to the initial version and is now part of a combined cell therapy-vaccine study. Andrew Allen, the Co-founder and CEO of Gritstone bio, emphasized the significance of the "off-the-shelf" neoantigen strategy for solid tumors, which is integral to the company's mission of developing highly potent vaccines. The SLATE platform, which is designed for quick application across a range of solid tumors, complements GRANITE, Gritstone's personalized vaccine program. The company is confident that both platforms could significantly enhance immune responses in cancer patients. 

Karin Jooss, the Executive Vice President and Head of R&D at Gritstone bio, pointed out the importance of understanding the mechanisms of therapeutic neoantigens and the ability to select and design antigens to elicit a potent immune response. The company's proprietary platform, EDGE™, was used to identify neoantigens based on shared mutations and HLA matching, leading to the development of SLATE-KRAS. 

The interim results from the SLATE 1/2 Study, involving patients with advanced or metastatic solid tumors, showed that the SLATEv1 vaccine, which includes 20 shared neoantigens, was safe, tolerable, and immunogenic. The vaccine's design was based on the unexpected immunodominance hierarchy, which influenced the therapeutic efficacy of multi-epitope vaccines. Gritstone bio is a clinical-stage biotechnology company dedicated to creating potent vaccines to treat and prevent diseases, including solid tumors. The company is advancing its product candidates through clinical trials and is focused on improving patient outcomes.

About Gritstone bio: Gritstone bio, Inc. is a clinical-stage biotechnology company listed on Nasdaq (GRTS), with a mission to develop potent vaccines. The company uses innovative vectors and payloads to activate the immune system against disease targets. They are independently and collaboratively working on a range of product candidates aimed at treating and preventing viral diseases and solid tumors.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Encouraging GTX-102 Trial Results in Angelman Syndrome Patients from Phase 1/2 Study by Ultragenyx
Pharma Pioneer
2 min read
Encouraging GTX-102 Trial Results in Angelman Syndrome Patients from Phase 1/2 Study by Ultragenyx
16 May 2024
April 15, 2024 —In a recent study, patients with Angelman syndrome demonstrated significant improvements in various areas after treatment with GTX-102.
Read →
TransCode Receives FDA Approval to Launch Phase 1/2 Study of TTX-MC138 for Advanced Solid Tumor Patients
Pharma Pioneer
2 min read
TransCode Receives FDA Approval to Launch Phase 1/2 Study of TTX-MC138 for Advanced Solid Tumor Patients
16 May 2024
TransCode Therapeutics, an RNA oncology company, has received approval from the U.S. Food and Drug Administration (FDA) to commence a Phase 1/2 clinical trial for its lead therapeutic candidate, TTX-MC138.
Read →
ORIC Initiates Dosing in Phase 1b Expansion for ORIC-114 in NSCLC Patients with Specific Mutations
Pharma Pioneer
2 min read
ORIC Initiates Dosing in Phase 1b Expansion for ORIC-114 in NSCLC Patients with Specific Mutations
16 May 2024
April 15, 2024 — ORIC Pharmaceuticals, a clinical-stage oncology company, has completed the dose escalation phase of its Phase 1b trial for ORIC-114.
Read →
Senti Bio Initiates Phase 1 Trial of SENTI-202 for Recurrent or Treatment-Resistant Blood Cancers
Latest Hotspot
3 min read
Senti Bio Initiates Phase 1 Trial of SENTI-202 for Recurrent or Treatment-Resistant Blood Cancers
15 May 2024
Senti Bio reports initial dosing in a Phase 1 trial for SENTI-202, targeting recurrent or treatment-resistant blood cancers like Acute Myeloid Leukemia.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.